Translating Glutamate: From Pathophysiology to Treatment

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879

Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses

Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330

Recent advances in the phencyclidine model of schizophrenia

(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881

The Neural Basis of Addiction: A Pathology of Motivation and Choice

Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757

Drug Addiction and Its Underlying Neurobiological Basis: Neuroimaging Evidence for the Involvement of the Frontal Cortex

Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020

Electrical synapses and their functional interactions with chemical synapses

Pereda, A. E. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3708 · Cited by 855

Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction

Ayalew, M., Le-Niculescu, H., Levey, D. F., Jain, N., Changala, B., Patel, S. D., Winiger, E. A., Breier, A. F., Shekhar, A., AMDUR, R. L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.37 · Cited by 390

Auditory dysfunction in schizophrenia: integrating clinical and basic features

Javitt, D. C., & Sweet, R. A. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4002 · Cited by 377

Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia

Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322

Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis

Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304

The neurobiology of depression in later-life: Clinical, neuropsychological, neuroimaging and pathophysiological features

Naismith, S. L., Norrie, L. M., Mowszowski, L., & Hickie, I. B. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.05.009 · Cited by 282

Add-on Treatment of Benzoate for Schizophrenia

Lane, H., Lin, C., Green, M. F., Hellemann, G., Huang, C., Chen, P., Tun, R., Chang, Y.-C., & Tsai, G. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2159 · Cited by 233

Targeting the Glutamatergic System to Treat Major Depressive Disorder: Rationale and Progress to Date

Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders

Hashimoto, K., Malchow, B., Falkai, P., & Schmitt, A. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0399-y · Cited by 224

Posteromedial cortex glutamate and GABA predict intrinsic functional connectivity of the default mode network

Kapogiannis, D., Reiter, D. A., Willette, A. A., & Mattson, M. P. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.029 · Cited by 211

Intracranial Self-Stimulation to Evaluate Abuse Potential of Drugs

Negus, S. S., & Miller, L. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007419 · Cited by 216

Thinking Outside the Cleft to Understand Synaptic Activity: Contribution of the Cystine-Glutamate Antiporter (System xc−) to Normal and Pathological Glutamatergic Signaling

Bridges, R., Lutgen, V., Lobner, D., & Baker, D. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003889 · Cited by 205

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205

Transcranial magnetic stimulation in the treatment of substance addiction

Gorelick, D. A., Zangen, A., & George, M. S. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12479 · Cited by 195

Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction

Pehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161

Clinically Significant Drug Interactions with Newer Antidepressants

Spina, E., Trifirò, G., & Caraci, F. (2011) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 164

Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings

Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Javitt, D. C., Lieberman, J. A., Abi‐Dargham, A., & Girgis, R. R. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.12.013 · Cited by 158

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial

Kantrowitz, J. T., Woods, S. W., Petkova, E., Cornblatt, B., Corcoran, C. M., Chen, H., Silipo, G., & Javitt, D. C. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00098-x · Cited by 148

Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial

Lin, C., Lin, C., Chang, Y.-C., Huang, Y.-J., Chen, P., Yang, H.-T., & Lane, H. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.12.006 · Cited by 138

The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies

Girgis, R. R., Kumar, S. S., & Brown, A. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.002 · Cited by 138

A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia

Downing, A. M., Kinon, B. J., Millen, B. A., Zhang, L., Liu, L., Ma, M., Brenner, R., Rayle, T. J., Nisenbaum, L., Zhao, F., et al. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0351-3 · Cited by 129

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms

Kantrowitz, J. T., Epstein, M. L., Lee, M., Lehrfeld, N., Nolan, K. A., Shope, C., Petkova, E., Silipo, G., & Javitt, D. C. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.027 · Cited by 123

Targeting of NMDA receptors in new treatments for schizophrenia

Hashimoto, K. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.934225 · Cited by 117

Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression

Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113

Twenty-five Years of Glutamate in Schizophrenia: Are We There Yet?

Javitt, D. C. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs100 · Cited by 108

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial

Javitt, D. C., Carter, C. S., Krystal, J. H., Kantrowitz, J. T., Girgis, R. R., Kegeles, L. S., Ragland, J. D., Maddock, R. J., Lesh, T. A., Tanase, C., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3572 · Cited by 100

N-acetylcysteine Pharmacology and Applications in Rare Diseases—Repurposing an Old Antioxidant

Sahasrabudhe, S. A., Terluk, M. R., & Kartha, R. V. (2023) · Antioxidants · doi:10.3390/antiox12071316 · Cited by 102

Hampered long-term depression and thin spine loss in the nucleus accumbens of ethanol-dependent rats

Spiga, S., Talani, G., Mulas, G., Licheri, V., Fois, G. R., Muggironi, G., Masala, N., Cannizzaro, C., Biggio, G., Sanna, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406768111 · Cited by 99

Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia

Kantrowitz, J. T., Hoptman, M. J., Leitman, D. I., Moreno-Ortega, M., Lehrfeld, J. M., Dias, E. C., Sehatpour, P., Laukka, P., Silipo, G. S., & Javitt, D. C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4603-14.2015 · Cited by 91

Impact of Ketamine on Neuronal Network Dynamics: Translational Modeling of Schizophrenia‐Relevant Deficits

Kocsis, B., Brown, R. E., McCarley, R. W., & Hajós, M. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12081 · Cited by 96

Independent and Additive Effects of Glutamic Acid and Methionine on Yeast Longevity

Wu, Z., Song, L., Liu, S., & Huang, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079319 · Cited by 89

Decreased mRNA expression for the two subunits of system xc−, SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: Evidence in support of the hypo-glutamatergic hypothesis of schizophrenia

Lin, C., Lin, P., Lin, C.-Y., Lin, C., Huang, C.-H., Huang, Y.-J., & Lane, H. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.007 · Cited by 91

Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism

Meinhardt, M. W., Pfarr, S., Fouquet, G., Rohleder, C., Meinhardt, M. L., Barroso-Flores, J., Hoffmann, R., Jeanblanc, J., Paul, E., Wagner, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2399 · Cited by 89

Mapping glutamate in subcortical brain structures using high‐resolution GluCEST MRI

Cai, K., Singh, A. K., Roalf, D. R., Nanga, R. P. R., Haris, M., Hariharan, H., Gur, R. C., & Reddy, R. D. (2013) · NMR in Biomedicine · doi:10.1002/nbm.2949 · Cited by 89

Zinc signaling and epilepsy

Doboszewska, U., Młyniec, K., Wlaź, A., Poleszak, E., Nowak, G., & Wlaź, P. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.013 · Cited by 81

Neurophysiological models for new treatment development in schizophrenia: early sensory approaches

Javitt, D. C. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12689 · Cited by 84

A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology

Javitt, D. C., Siegel, S. J., Spencer, K., Mathalon, D. H., Hong, L. E., Martínez, A., Ehlers, C. L., Abbas, A. I., Teichert, T., Lakatos, P., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0697-9 · Cited by 84

Glycine transport inhibitors in the treatment of schizophrenia

Javitt, D. C. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_12 · Cited by 83

Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder

Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83

12-Week, Placebo-Controlled Trial of Add-on Riluzole in the Treatment of Childhood-Onset Obsessive–Compulsive Disorder

Grant, P. J., Joseph, L. A., Farmer, C., Luckenbaugh, D. A., Lougee, L., Zarate, C. A., & Swedo, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.343 · Cited by 80

Glutamate modulates resting state activity in the perigenual anterior cingulate cortex – A combined fMRI–MRS study

Enzi, B., Duncan, N. W., Kaufmann, J., Tempelmann, C., Wiebking, C., & Northoff, G. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.039 · Cited by 76

Future Directions for Research in Autism Spectrum Disorders

Damiano, C. R., Mazefsky, C. A., White, S. W., & Dichter, G. S. (2014) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2014.945214 · Cited by 86

Perisynaptic astroglial processes: dynamic processors of neuronal information

Ghézali, G., Dallérac, G. M., & Rouach, N. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1070-3 · Cited by 79

Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression

Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 68

Convergent Findings for Abnormalities of the NF-κB Signaling Pathway in Schizophrenia

Roussos, P., Katsel, P., Davis, K. L., Giakoumaki, S. G., Siever, L. J., Bitsios, P., & Haroutunian, V. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.215 · Cited by 69

Chronic Cigarette Smoking in Healthy Middle-Aged Individuals Is Associated With Decreased Regional Brain N-acetylaspartate and Glutamate Levels

Durazzo, T. C., Meyerhoff, D. J., Mon, A., Abé, C., Gazdzinski, S. P., & Murray, D. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.029 · Cited by 69

The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders

Peyrovian, B., Rosenblat, J. D., Pan, Z., Iacobucci, M., Brietzke, E. M., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.001 · Cited by 76

Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia

Banerjee, A., Wang, H.-Y., Borgmann‐Winter, K. E., MacDonald, M. L., Kaprielian, H., Stucky, A., Kvasic, J., Egbujo, C. N., Ray, R., Talbot, K., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.115 · Cited by 65

An update on NMDA antagonists in depression

Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 67

Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine – a quantitative EEG study in rats

Leiser, S. C., Pehrson, A. L., Robichaud, P. J., & Sánchez, C. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12782 · Cited by 63

BNST GluN2D-Containing NMDA Receptors Influence Anxiety- and Depressive-like Behaviors and ModulateCell-Specific Excitatory/Inhibitory Synaptic Balance

Salimando, G. J., Hyun, M., Boyt, K. M., & Winder, D. G. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0270-20.2020 · Cited by 63

R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome

Qin, M., Huang, T., Kader, M., Krych, L., Xia, Z., Burlin, T., Zeidler, Z., Zhao, T., & Smith, C. B. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv034 · Cited by 62

Chronic unpredictable stress promotes cell-specific plasticity in prefrontal cortex D1 and D2 pyramidal neurons

Anderson, E. M., Gomez, D. M., Caccamise, A. J., McPhail, D., & Hearing, M. C. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100152 · Cited by 59

Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders

Yan, L.-Q., Shamir, A., Skirzewski, M., Leiva‐Salcedo, E., Kwon, O., Karavanova, I. D., Paredes, D., Malkesman, O., Bailey, K. R., Vullhorst, D., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.22 · Cited by 59

Higher Glutamate + Glutamine and Reduction of N-acetylaspartate in Posterior Cingulate According to Age Range in Patients with Cognitive Impairment and/or Pain

Fayed, N. M., Andres, E. M., Viguera, L., Modrego, P. J., & García‐Campayo, J. (2014) · Academic Radiology · doi:10.1016/j.acra.2014.04.009 · Cited by 54

Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies

Ross, S. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.04.002 · Cited by 54

Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines

Chávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas, J. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/7943481 · Cited by 60

Region-specific elevations of glutamate + glutamine correlate with the sensory symptoms of autism spectrum disorders

He, J. L., Oeltzschner, G., Mikkelsen, M. E., Deronda, A. C., Harris, A. D., Crocetti, D., Wodka, E. L., Mostofsky, S. H., Edden, R. A. E., & Puts, N. A. J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01525-1 · Cited by 58

Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment

Hung, C.-C., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189718 · Cited by 52

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

Calleja‐Conde, J., Morales-Garcia, J. A., Echeverry‐Alzate, V., Bühler, K., Giné, E., & López‐Moreno, J. A. (2022) · Addiction Biology · doi:10.1111/adb.13229 · Cited by 58

Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders

Thalman, C., Horta, G., Qiao, L., Endle, H., Tegeder, I., Cheng, H., Laube, G., Sigurdsson, T., Hauser, M. J., Tenzer, S., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0053-1 · Cited by 52

Glutamatergic Deficits in Schizophrenia – Biomarkers and Pharmacological Interventions within the Ketamine Model

Haaf, M., Leicht, G., Ćurić, S., & Mulert, C. (2018) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180620112528 · Cited by 52

Molecular cause and functional impact of altered synaptic lipid signaling due to a prg‐1 gene SNP

Vogt, J., Yang, J., Mobascher, A., Cheng, J., Li, Y., Liu, X., Baumgart, J., Thalman, C., Kirischuk, S., Unichenko, P., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505677 · Cited by 50

Serotonin and Glutamate Interactions in Preclinical Schizophrenia Models

Shah, U. H., & González‐Maeso, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00044 · Cited by 49

Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects

Mehta, M. A., Schmechtig, A., Kotoula, V., McColm, J., Jackson, K. A., Brittain, C. F., Tauscher‐Wisniewski, S., Kinon, B. J., Morrison, P. D., Pollak, T. A., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4877-9 · Cited by 47

A Randomized, Double-Blind, Placebo-Controlled, Trial of Lamotrigine Therapy in Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence

Brown, E. S., Sunderajan, P., Hu, L. T., Sowell, S. M., & Carmody, T. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.90 · Cited by 46

Mismatch negativity: A simple and useful biomarker of N-methyl-d-aspartate receptor (NMDAR)-type glutamate dysfunction in schizophrenia

Avissar, M., & Javitt, D. C. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.11.006 · Cited by 45

Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression

Sepulveda-Orengo, M. T., Healey, K. L., Kim, R., Auriemma, A. C., Rojas, J. M., Woronoff, N., Hyppolite, R., & Reissner, K. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.244 · Cited by 45

Temporal dynamics of miRNAs in human DLPFC and its association with miRNA dysregulation in schizophrenia

Hu, Z., Gao, S., Lindberg, D. M., Panja, D., Wakabayashi, Y., Li, K., Kleinman, J. E., Zhu, J., & Li, Z. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0538-y · Cited by 45

N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia

Kantrowitz, J. T. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.003 · Cited by 40

Ketamine: The final frontier or another depressing end?

Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 41

Variable prenatal stress results in impairments of sustained attention and inhibitory response control in a 5-choice serial reaction time task in rats

Wilson, C. A., Schade, R., & Terry, A. V. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.040 · Cited by 40

Inhibition of STEP61 ameliorates deficits in mouse and hiPSC-based schizophrenia models

Xu, J., Hartley, B. J., Kurup, P. K., Phillips, A. W., Topol, A., Xu, M., Ononenyi, C., Foscue, E. P., Ho, S.-M., Baguley, T. D., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.163 · Cited by 40

Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma

Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073798 · Cited by 40

Extracellular Glutamate in the Nucleus Accumbens Is Nanomolar in Both Synaptic and Non-synaptic Compartments

Chiu, D. N., & Jahr, C. E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.047 · Cited by 43

Effects of (R)‐(−)‐5‐methyl‐1‐nicotinoyl‐2‐pyrazoline on glutamate transporter 1 and cysteine/glutamate exchanger as well as ethanol drinking behavior in male, alcohol‐preferring rats

Aal-Aaboda, M. S., Alhaddad, H., Osowik, F. A., Nauli, S. M., & Sari, Y. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23554 · Cited by 37

Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia

Ballesteros, A., Summerfelt, A., Du, X., Jiang, P., Chiappelli, J., Tagamets, M., O’Donnell, P., Kochunov, P., & Hong, L. E. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.05.021 · Cited by 34

Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome

Pretto, D. I., Kumar, M., Cao, Z., Cunningham, C. L., Durbin-Johnson, B. P., Qi, L., Berman, R. F., Noctor, S. C., Hagerman, R. J., Pessah, I. N., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.009 · Cited by 34

Functional crosstalk of the glycine transporter GlyT1 and NMDA receptors

Piniella, D., & Zafra, F. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109514 · Cited by 35

Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions

Zádor, F., Nagy-Grócz, G., Kékesi, G., Dvorácskó, S., Szűcs, E., Tömböly, C., Horváth, G., Benyhe, S., & Vécsei, L. (2019) · Molecules · doi:10.3390/molecules24203709 · Cited by 33

Group II Metabotropic Glutamate Receptor Agonist LY379268 Regulates AMPA Receptor Trafficking in Prefrontal Cortical Neurons

Wang, M.-J., Li, Y., Snyder, M. A., Wang, H., Li, F., & Gao, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061787 · Cited by 33

Glutamatergic candidate genes in autism spectrum disorder: an overview

Chiocchetti, A. G., Bour, H. S., & Freitag, C. M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1161-y · Cited by 31

Small Molecule Screening Identifies Regulators of the Transcription Factor ΔFosB

Wang, Y., Ceseña, T. I., Ohnishi, Y. H., Burger-Caplan, R., Lam, V., Kirchhoff, P. D., Larsen, S. D., Larsen, M. J., Nestler, E. J., & Rudenko, G. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000235 · Cited by 30

Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date

Fung, L. K., & Hardan, A. Y. (2015) · CNS Drugs · doi:10.1007/s40263-015-0252-0 · Cited by 28

Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy

Nagy, D., Stoiljković, M., Menniti, F. S., & Hajós, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.298 · Cited by 29

Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058

Sehatpour, P., Javitt, D. C., Baun, H. M. D., Carlson, M., Beloborodova, A. V., Margolin, D. H., Carlton, M. B. L., Brice, N., & Kantrowitz, J. T. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01170-8 · Cited by 27

Neuroprotective effect of penehyclidine hydrochloride on focal cerebral ischemia-reperfusion injury.

Yu, C., & Jun-ke, W. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.07.006 · Cited by 27

Effects of Electroconvulsive Therapy on Some Inflammatory Factors in Patients With Treatment-Resistant Schizophrenia

Kartalcı, Ş., Karabulut, A. B., Erbay, L. G., & Acar, C. (2016) · Journal of Ect · doi:10.1097/yct.0000000000000303 · Cited by 26

Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate–Type Glutamate Receptor Function

Kantrowitz, J. T., Swerdlow, N. R., Dunn, W., & Vinogradov, S. (2018) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.02.002 · Cited by 26

Increased Fear Memory and Glutamatergic Modulation in Compulsive Drinker Rats Selected by Schedule-Induced Polydipsia

Prados-Pardo, Á., Martín-González, E., Mora, S., Merchán, A., Flores, P., & Moreno, M. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00100 · Cited by 25

Dietary glutamate and the brain: In the footprints of a Jekyll and Hyde molecule

Onaolapo, A. Y., & Onaolapo, O. J. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2020.07.001 · Cited by 25

Hippocampal glutamatergic/NMDA receptor functioning in bipolar disorder: A study combining mismatch negativity and proton magnetic resonance spectroscopy

Chitty, K. M., Lagopoulos, J., Hickie, I. B., & Hermens, D. F. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.05.002 · Cited by 24

Chronic Effects of Cannabis Use on the Auditory Mismatch Negativity

Greenwood, L., Broyd, S. J., Croft, R. J., Todd, J., Michie, P. T., Johnstone, S. J., Murray, R. M., & Solowij, N. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.05.035 · Cited by 24

Autoimmune-induced glutamatergic receptor dysfunctions: Conceptual and psychiatric practice implications

Rosenthal-Simons, A., Durrant, A. R., & Heresco‐Levy, U. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.008 · Cited by 25

Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway

Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01086-1 · Cited by 23

Effects of a Novel Beta Lactam Compound, MC-100093, on the Expression of Glutamate Transporters/Receptors and Ethanol Drinking Behavior of Alcohol-Preferring Rats

Alhaddad, H., Wong, W., Abou-Gharbia, M. A., Childers, W. E., Melenski, E., Bell, R. L., & Sari, Y. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001147 · Cited by 22

Maturation- and sex-sensitive depression of hippocampal excitatory transmission in a rat schizophrenia model

Patrich, E., Piontkewitz, Y., Peretz, A. S., Weiner, I., & Attali, B. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.08.021 · Cited by 27

The trading zone of autism genetics: Examining the intersection of genomic and psychiatric classification

Navon, D., & Eyal, G. (2014) · BioSocieties · doi:10.1057/biosoc.2014.18 · Cited by 21

In Situ Electrically Resettable Field‐Effect Transistor Biosensors for Continuous and Multiplexed Neurotransmitter Detection

Xiao, B., Li, T., Cao, X., Zhang, Y., He, J., Xiao, M., & Zhang, Z. (2025) · Advanced Science · doi:10.1002/advs.202504497 · Cited by 21

Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors

Harvey, B. D., Siok, C. J., Kiss, T., Volfson, D., Grimwood, S., Shaffer, C. L., & Hajós, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.020 · Cited by 21

Role of Central Glutamatergic Neurotransmission in the Pathogenesis of Psychiatric and Behavioral Disorders

Wang, S., & Yang, T. (2005) · Drug News & Perspectives · doi:10.1358/dnp.2005.18.9.953668 · Cited by 17

Glutamatergic Dysregulation in Depression, Schizophrenia, and Addiction: Mechanisms and Therapeutic Strategies

Shi, W., & Bai, J. (2026) · Actas Españolas de Psiquiatría · doi:10.62641/aep.2307

Glutamatergic Pathways

Smith, Y. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-852-6_3 · Cited by 1

Translational medicine of the glutamate AMPA receptor

Miyazaki, T., Hiroki, A. B. E., Uchida, H., & Takahashi, T. (2021) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.97.001 · Cited by 12

Glutamate as a therapeutic target in psychiatric disorders

Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 534